Should Pharma Invest in R&D or Search for External Drug Candidates?

Melton, customer advocacy executive at Magnolia, discusses how new technologies can be used to ensure data is accurate.

Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.

Alder, CEO of Gain Therapeutics, discusses how the Magellan platform was used in the creation of GT-02287.

According to results of the study, 46% of patients with giant cell arteritis administered Rinvoq achieved sustained remission from weeks 12 to 52.

Through embracing connected and tech-enabled services and devices, new avenues and opportunities exist for greater clinical trial flexibility in drug research.

Greater Than One’s Chief Strategy Officer, Andrew Bast, shares his takeaways from 2024 Rare Disease Summit in Philadelphia, PA.